« Health Insurance Company Pays Its Policy Holders to Stay Fit | Main | Quest Diagnostics and Lab Corp Business Models Becoming Obsolete »



Not sure I would go with "no flaws." So far they seem to be refusing to allow thorough comparison with existing technologies and methods. This is fine but if these results are to have any validity for most significant patient care they will need to have these comparisons. Otherwise, every test they run is going to have to be repeated when the patient actually needs treatment. Running everything as an LDT to avoid regulation and quality issues is ok to start, but to establish a significant footprint outside of walgreens or similar places they have to make sure people can trust their results. Their business model also seems to overvalue some of the advantages they have - like the "price" of the test for which they are comparing to non-real existing lab prices. Pricing is much more problematic when insurance reimbursement is at play. Pricing will come down elsewhere if their technology takes off. And their assumptions about lab TAT are pretty weak, although their ability to do certain DNA tests would be a significant difference. The small amount of blood is important, but probably not as important as reporters and media like to think.

The comments to this entry are closed.

Corporate Underwriters



Search Lab Soft News

  • Google


Subscribe to Lab Soft News (Email and RSS Feeds)

Your email address:

Powered by FeedBlitz

May 2020

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
Blog powered by Typepad
Member since 12/2005